NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts by X. Fan et al.
CANCER STEM CELLS
NOTCH Pathway Blockade Depletes CD133-Positive Glioblastoma
Cells and Inhibits Growth of Tumor Neurospheres and Xenografts
XING FAN,a,b LEILA KHAKI,c THANT S. ZHU,a MARY E. SOULES,a CAROLINE E. TALSMA,a NAHEED GUL,c
CHERYL KOH,c JIANGYANG ZHANG,d YUE-MING LI,h JAREK MACIACZYK,i GUIDO NIKKHAH,i
FRANCESCO DIMECO,g,j SARA PICCIRILLO,k ANGELO L. VESCOVI,k CHARLES G. EBERHARTc,e,f
aDepartments of aNeurosurgery and bCell and Developmental Biology, University of Michigan Medical School,
Ann Arbor, Michigan, USA; Departments of cPathology, dRadiology, eOncology, fOphthalmology, and
gNeurological Surgery, Johns Hopkins University, Baltimore, Maryland, USA; hPharmacology & Chemistry
Program, Memorial Sloan-Kettering Cancer Center, New York, New York, USA; iDepartment of Stereotactic and
Functional Neurosurgery, University of Freiburg, Freiburg, Germany; jDepartment of Neurosurgery, Istituto
Nazionale Neurologico C. Besta, Milan, Italy; kDepartment of Biotechnology and Biosciences, University of
Milan Bicocca, Milan, Italy;
Key Words. Cancer Stem Cell • NOTCH • Glioblastoma • c-Secretase inhibitor
ABSTRACT
Cancer stem cells (CSCs) are thought to be critical for the
engraftment and long-term growth of many tumors, includ-
ing glioblastoma (GBM). The cells are at least partially
spared by traditional chemotherapies and radiation thera-
pies, and ﬁnding new treatments that can target CSCs may
be critical for improving patient survival. It has been
shown that the NOTCH signaling pathway regulates nor-
mal stem cells in the brain, and that GBMs contain stem-
like cells with higher NOTCH activity. We therefore used
low-passage and established GBM-derived neurosphere cul-
tures to examine the overall requirement for NOTCH activ-
ity, and also examined the effects on tumor cells expressing
stem cell markers. NOTCH blockade by c-secretase inhibi-
tors (GSIs) reduced neurosphere growth and clonogenicity
in vitro, whereas expression of an active form of NOTCH2
increased tumor growth. The putative CSC markers
CD133, NESTIN, BMI1, and OLIG2 were reduced follow-
ing NOTCH blockade. When equal numbers of viable cells
pretreated with either vehicle (dimethyl sulfoxide) or GSI
were injected subcutaneously into nude mice, the former
always formed tumors, whereas the latter did not. In vivo
delivery of GSI by implantation of drug-impregnated poly-
mer beads also effectively blocked tumor growth, and sig-
niﬁcantly prolonged survival, albeit in a relatively small
cohort of animals. We found that NOTCH pathway inhibi-
tion appears to deplete stem-like cancer cells through
reduced proliferation and increased apoptosis associated
with decreased AKT and STAT3 phosphorylation. In sum-
mary, we demonstrate that NOTCH pathway blockade
depletes stem-like cells in GBMs, suggesting that GSIs may
be useful as chemotherapeutic reagents to target CSCs in
malignant gliomas. STEM CELLS 2010;28:5–16
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INTRODUCTION
More than 41,000 people are diagnosed with primary brain
tumors each year in the U.S. [1], and glioblastomas (GBMs)
are the most common malignant brain tumors in adults [2].
Even with advances in surgery, imaging, chemotherapy, and
radiation therapy over the past three decades, more than
70% of GBM patients still die within 2 years of diagnosis
[1–3]. New strategies to treat this deadly disease are desper-
ately needed [1]. In this study, we focus on the potential
therapeutic role of NOTCH pathway inhibition, and the
requirement for ongoing NOTCH signaling in stem-like tu-
mor cells.
There is emerging evidence that a small population of
cancer stem cells (CSCs) within neoplasms is responsible for
long-term tumor propagation, with initial studies focused on
leukemia [4]. Several groups have subsequently demonstrated
that stem-like cells exist in brain tumors, including GBMs [4–
9]. CSC markers such as CD133 and side population have
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been used to prospectively isolate a small fraction of cells in
human and rodent brain tumors with a signiﬁcantly increased
potential to generate tumor neurospheres and xenografts [5, 7,
8, 10, 11]. Tumor-derived neurospheres also have a genetic
proﬁle that remains closer to that of the tumor from which
they are isolated than traditional adherent GBM cell lines
maintained in high serum [12]. In addition, GBMs propagated
as neurospheres maintain stem-like subpopulations, and more
accurately replicate the inﬁltrating growth patterns seen in pri-
mary tumors [9, 12]. GBM neurosphere cultures thus provide
an improved pathological model, and may also facilitate the
discovery of new therapeutic reagents that can target the
stem-like or xenograft-initiating cells required for long-term
tumor growth.
The Notch locus was ﬁrst described by Morgan in a
strain of Drosophila with notched wing blades [13]. The
gene was subsequently cloned as a cell surface receptor
[14], playing a key role in the development of many differ-
ent cell types and tissues, including neurons in the central
nervous system [15–18]. NOTCH signaling is initiated when
transmembrane ligands on one cell bind NOTCH receptors
on an adjacent cell and cause the c-secretase-mediated pro-
teolytic release of the NOTCH intracellular domain (NICD)
[19, 20]. NICD then translocates into the nucleus where it
interacts with the transcriptional cofactor CBF1 and acti-
vates targets such as the HES and HEY genes, which modu-
late neuronal and glial differentiation [21]. In vertebrates, at
least four NOTCH receptors (NOTCH 1-4), ﬁve ligands
(JAG1, 2, DLL1, 3, 4), and multiple effector molecules
(HES1-6, HEY1, 2 L) have been identiﬁed [21, 22]. NOTCH
ligands, receptors, and targets have been found in a wide
range of neoplasms, including lung, breast, cervix, head/
neck, renal, and pancreas carcinoma, neuroblastoma, my-
eloma, melanoma, choroid plexus tumor, medulloblastoma,
and GBM [20, 22–33]. In many of these tumor types, it has
been shown that increased NOTCH activity promotes tumor
growth, whereas NOTCH pathway blockade inhibits prolif-
eration and/or survival. Inhibition of NOTCH signaling is
therefore a promising therapeutic avenue in a wide range of
cancers.
We and others have demonstrated that the NOTCH sig-
naling pathway plays an important role in the pathogenesis
of medulloblastoma and GBM [28, 34–36], and that these
malignant brain tumors contain stem-like cancer cells with
higher NOTCH activity [9, 12, 32]. It has recently been
reported that common chemotherapeutic drugs, including
temozolomide, carboplatin, paclitaxel (Taxol), and etopo-
side (VP16), as well as traditional radiation therapy, pre-
dominantly targeted the CD133-negative population, and
spared or enriched the CD133-positive population [37, 38].
We have also observed an increase in the stem-like subpo-
pulation in GBM-derived neurosphere lines following radi-
ation therapy [39]. Thus, conventional chemotherapies and
radiation therapies appear to effectively remove only bet-
ter-differentiated cells, while leaving many GBM CSCs
alive. The NOTCH pathway represents a possible target in
stem-like glioma cells, as several groups have shown that
GBM CSCs express NOTCH family genes, and that tumor-
derived neurospheres have elevated NOTCH activity [9, 12,
32]. It is known that NOTCH regulates normal neural stem
cell self-renewal and differentiation [40, 41], and that
CSCs share many characteristics with their normal cog-
nates, including the signaling pathways that regulate self-
renewal. In the present study, we used both established and
low-passage GBM cultures as a model to examine the




GBM neurosphere cultures were maintained in Neurocult medium
(Stem Cell Technologies, Vancouver, BC, Canada, http://
www.stemcell.com) supplemented with epidermal growth factor
(20 ng/ml) and ﬁbroblast growth factor (10 ng/ml). Cell pools
and stable subclones transfected with NOTCH2 intracellular do-
main (NICD2) were generated as previously described [34, 42].
For treatment studies, cells were plated and allowed to grow
overnight in Neurocult medium; Neurocult was then replaced the
next morning with medium containing c-secretase inhibitor 18
(GSI-18) dissolved in dimethyl sulfoxide (DMSO) at the concen-
trations of 0.4-50 lM. RNA and protein extractions and all cell-
based assays were performed 2-5 days after drug application. Cell
mass was measured using CellTiter assays according to the
instructions of the manufacturer (Promega, Madison, WI, http://
www.promega.com). Cell number and viability were assessed
using the Guava PCA and Viacount reagent according to instruc-
tions (Guava Technologies, Hayward, CA, http://www.guavatech-
nologies.com). All experiments were performed in triplicate.
c-Secretase Inhibitor Synthesis
The potent c-secretase inhibitor [11-endo]-N-(5,6,7,8,9,10-hexahy-
dro-6,9-methanobenzo[a] [8]annulen-11-yl)-thiophene-2-sulfona-
mide was listed as compound 18 in the recent report by Lewis
et al. [43] describing its synthesis and testing, and we refer to it
as GSI-18. It was synthesized as previously described [43], and
its identity and quality were conﬁrmed by nuclear magnetic reso-
nance and mass spectral analysis. The biological activity of this
inhibitor against c-secretase was conﬁrmed using in vitro and
cell-based assays as previously described [44]. MRK-003 was
generously provided by Merck Research Laboratories (Boston,
MA, http://www.merck.com) [43].
Immunocytochemistry
The GBM neurosphere lines and low-passage cultures were
seeded in 12-well tissue culture plates overnight. After treating
with 2 lM GSI-18 for 2-5 days, cells were washed with phos-
phate-buffered saline (PBS), spun down onto slides, and ﬁxed
using 4% paraformaldehyde solution in PBS at room temperature
for 30 minutes. Cells were then permeabilized with 0.4% Triton
X-100 in PBS for 5 minutes at room temperature, washed with
PBS, and incubated in 5% bovine serum albumin (BSA)-PBS for
1 hour and then in 1:1,000 anti-NESTIN antibody (Chemicon,
Temecula, CA, http://www.chemicon.com) or 1:500 anti-Ki-67
(DAKO, Glostrup, Denmark, http://www.dako.com) in 1% BSA-
PBS for 2 hours. After washing with PBS, a ﬁnal 60-minute incu-
bation with a 1:300 dilution of cyanin 3 (Cy3)-conjugated goat
anti-mouse and Cy2-conjugated goat anti-rabbit secondary anti-
bodies (Jackson Immunoresearch Laboratories, West Grove, PA,
http://www.jacksonimmuno.com) diluted in PBS containing 1%
BSA was done. After washing with PBS, cells were then counter-
stained with 40,6-diamidino-2-phenylindole (Vector Laboratories,
Burlingame, CA, http://www.vectorlabs.com), mounted, and
visualized with ﬂuorescence microscope (Carl Zeiss, Jena, Ger-
many, http://www.zeiss.com); 10 high-power ﬁelds were photo-
graphed and counted. For immunocytochemical evaluation of in-
tracranial xenografts, frozen sections of cryoprotected brains were
stained with anti-human antibody (1:100; Millipore, Billerica,
MA, http://www.millipore.com).
Flow Cytometric Analyses
Flow cytometric analysis of CD133 was done with antibodies from
Miltenyi Biotec (Auburn, CA, http://www.miltenyibiotec.com)
according to the instructions of the manufacturer using a FACSCa-
libur (Becton Dickinson, San Jose, CA, http://www.bd.com) with
CELLQuest Version 3.3 software (Becton Dickinson, San Jose,
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CA, http://www.bd.com) [42]. In brief, cells were blocked in Fc re-
ceptor blocking reagent and incubated with CD133/1 (AC133)-phy-
coerythrin antibody (Miltenyi Biotec) for 10 minutes in the dark at
4C. Then cells were washed and resuspended in 500 lL buffer
(PBS containing 0.5% BSA and 2 mM EDTA). Cells expressing
levels of CD133 higher than those seen in immunoglobulin G
(IgG) controls were considered positive. Experiments measuring
CD133 were repeated two to three times for each line and error
bars represent the mean and SE.
Real-Time Reverse Transcription-Polymerase
Chain Reaction
Quantitative reverse transcription-polymerase chain reaction (RT-
PCR) for NOTCH1, NOTCH2, and HES1 was done as previously
described [34, 45], with all reactions normalized to actin (Applied
Biosystems, Foster City, CA, http://www.appliedbiosystems.com).
Commercially available Assay on Demand TaqMan (Applied
Biosystems, Foster City, CA, http://www.appliedbiosystems.com)
primers and probes were used to measure mRNA for CD133,
NESTIN, BMI1, OLIG2, HES5, and HEY1. Each quantitative RT-
PCR reaction was done in triplicate and error bars represent SE.
Protein Analysis
Western blots contained 20 lg of protein per lane on a 10% Tris-
glycine SDS-polyacrylamide gel electrophoresis gel (Invitrogen,
Carlsbad, CA, http://www.invitrogen.com) and were electropho-
resed for several hours in 1  Tris-glycine (TG)-SDS buffer
(Amresco, Solon, OH, http://www.amresco-inc.com). Proteins
were transferred to 0.45-lm Optitran nitrocellulose (Schleicher &
Schuell, Keene, NH, http://www.schleicher-schuell.com) in 1
Tris-glycine buffer (Amresco). Blots were blocked in PBS con-
taining 5% nonfat dry milk powder and incubated overnight at
4C with antibodies directed against HES1 (1:2,000; kind gift of
Dr. Tetsuo Sudo, Toray Industries, Tebiro, Kamakura, Japan,
http://www. toray.com), cleaved caspase-3 (Asp175) (1:1,000;
Cell Signaling Technology, Beverly, MA, http://www.cellsignal.-
com), phosphorylated Akt (Ser473) and total Akt (1:1,000; Cell
Signaling Technology), phospho-STAT3 (pSer727) and total
STAT3 (1:1,000; Afﬁnity BioReagents, Golden, CO, http://
www.bioreagents.com), or glyceraldehyde-3-phosphate dehydro-
genase (1:20,000; Research Diagnostics, Flanders, NJ, http://
www.researchd.com). Blots were then washed several times with
PBS containing 0.1% Tween 20 and incubated in peroxidase-con-
jugated IgG diluted 1:2,000 in blocking solution. After washing
several times in PBS with 0.1% Tween 20, blots were developed
with enhanced chemiluminescence reagent (Pierce, Rockford, IL,
http://www. piercenet.com) and exposed to ﬁlm.
Flank and Intracranial Xenograft Tumors
For ﬂank xenograft tumors, 5  105 viable GBM neurosphere
cells were mixed 1:1 with Matrigel (BD Biosciences, San Jose,
CA, http://www.bdbiosciences.com) and a total volume of 200 ll
was injected s.c. into each ﬂank of ether-anesthetized 4-week-old
female nude mice. Measurements of tumor size in the long and
short axes were made weekly and estimates of volume were
made using the following formula: width2  length  0.52 [46].
For intracranial xenografts, injection guide holes were produced
in anesthetized animals by twirling an 18-gauge beveled needle
to provide access to the intracranial space. Fifty thousand viable
cells in 2 ll of PBS were used for intracranial injection into the
right striatum (0.2 lL/minute) by stereotactic injection through a
glass pipette connected to a Hamilton syringe. The following
coordinates were used: antero-posterior ¼ 0; medio-lateral ¼ 2.5
mm; dorso-ventral ¼ 3.5 mm [9]. The skin was sutured following
injection. Fifteen days after initial injection, the NOTCH inhibitor
was delivered using polymer-based beads soaked with GSI-18
into the tumor beds as described previously [47]. DMSO-soaked
beads were used as controls. Tumor growth was monitored by
magnetic resonance imaging (MRI) scanning at 6 weeks after
GSI treatment, but survival was used as the primary endpoint in
these studies. In vivo MRI studies were performed on a horizontal
9.4 T MR scanner (Bruker Biospin, Billerica, MA, http://
www.bruker-biospin.com) with a triple-axis gradient and an animal
imaging probe. The scanner was also equipped with a physiological
monitoring system (EKG, respiration, and body temperature). Mice
were anesthetized with isoﬂurane (1%) together with oxygen and air
at 1:3 ratio via a vaporizer and a facial mask. We used a 40-mm di-
ameter birdcage coil for the radio frequency transmitter and re-
ceiver. Temperature was maintained by a heating block built into
the gradient system. Respiration was monitored throughout the
entire scan and was used to synchronize the start of each acquisi-
tion. Multiple slice T2-weighted MRIs were acquired with the fol-
lowing parameters: fast spin echo sequence with an echo train
length of 4, echo time ¼ 35 ms, repetition time ¼ 3,000 ms, imag-
ing resolution ¼ 0.1 mm  0.1 mm per pixel, slice thickness ¼ 0.3
mm, total imaging time of 30 minutes with respiratory triggering.
Statistical analysis
Statistical analyses were done using GraphPad Prism 4 (GraphPad
Software, http://www.graphpad.com). Data graphed with error
bars represent mean and SE from experiments done in triplicate
unless otherwise noted. A two-sided Student’s t test was used to
determine the signiﬁcance of any differences.
RESULTS
GBM Neurospheres Are Sensitive to NOTCH
Pathway Blockade In Vitro
We initially studied well-characterized HSR-GBM1 neuro-
sphere cultures (Fig. 1A), which were derived from a single
tumor [9] and grown for several years as three independent
sublines. The stem cell marker CD133 is expressed in these
GBM-derived neurospheres, as detected using ﬂow cytometry,
in approximately 70% of the tumor cells (Fig. 1A). This line
was previously shown to express markers of NOTCH activity
at the time it was established [9], and we conﬁrmed protein
expression of the NOTCH pathway target HES1 in the tumor
neurospheres (Fig. 1B).
NOTCH pathway blockade for 48 hours using 2 lM c-secre-
tase inhibitor (GSI-18) decreased levels of HES1 protein in the
HSR-GBM1 neurospheres by more than 80% (quantiﬁed by den-
sitometry on the Western blot in Fig. 1B), and no HES1 was
detected when 10 lM or higher concentrations of the drug were
used (Fig. 1B). Because HES1 can be regulated by multiple path-
ways, we also examined two other markers of NOTCH signaling,
HES5 expression and formation of the activated NOTCH1 intra-
cellular domain. Both were decreased in a dose-dependent fash-
ion by GSI-18 (Fig. 1C, 1D), providing additional conﬁrmation
of baseline NOTCH activity and pharmacologic inhibition of the
pathway in tumor neurospheres. GSI-18 reduced growth of all
three HSR-GBM1 sublines in vitro in a dose-dependent fashion
(Fig. 1E). In contrast, the growth of normal human astrocytes
was not signiﬁcantly affected by the same level of GSI-18 (Fig.
1F), indicating that this agent does not nonselectively inhibit pro-
liferation of astrocytic cells. Two slower-growing established
GBM neurosphere lines (HSR-GBM2 and HSR-GBM3) were
also inhibited in a dose-dependent fashion by GSI-18 (Fig. 1G
and data not shown). The fact that HES1 mRNA in these GBM
neurosphere lines was expressed at levels within the range seen
in 24 snap-frozen GBM samples suggests they had biologically
relevant levels of NOTCH activity (Fig. 1H).
To help exclude the possibility that the effects of GSI-18
were nonspeciﬁc, we also used another c-secretase inhibitor
with a signiﬁcantly different structure, MRK-003. This second
compound also suppressed HSR-GBM1 growth and HES1 lev-
els in a dose-dependent fashion (Fig. 1I, 1J). Finally, we analyzed
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the growth of GBM neurospheres derived from four different
tumors and grown for relatively few passages (6-20). High
NOTCH activity in these cultures was conﬁrmed by NOTCH tar-
get gene expression (Fig. 1K). Growth of all four lines (SC, DM,
KO, and TZ) was inhibited 70% or more by 10 lM MRK-003,
whereas three of the lines (SC, KO, and TZ) showed a modest
growth suppression by 2 lM MRK-003 (Fig. 1L and data not
shown). These studies indicate that both long-established and
lower-passage GBM-derived neurospheres require ongoing
NOTCH signaling for growth in culture.
Activation of NOTCH2 in GBM Neurospheres
Increases Their Growth In Vitro
To examine whether activation of NOTCH signaling in GBM
neurospheres is sufﬁcient to increase tumor growth, we intro-
duced a truncated, constitutively active form of the NOTCH2
receptor (NICD2) into GBM neurosphere lines using either
stable transfection or transient expression following infection
by adenovirus we generated previously [34]. We used NICD2
in these experiments as NOTCH2 receptor protein has been
shown to be highly expressed in glioblastoma [48]. Following
NICD2 transfection and selection, HSR-GBM1 cells had sig-
niﬁcantly increased mRNA levels of NOTCH2 and the path-
way target HES1 (Fig. 2A–2C). The elevated NOTCH2 sig-
naling following transfection of NICD2 was associated with
an approximately twofold increase in growth over 5 days in
culture (Fig. 2D). Transient viral delivery of NICD2 also sig-
niﬁcantly increased the growth rate of GBM-derived neuro-
spheres, albeit to a lesser degree (Fig. 2E). This less robust
induction of growth may reﬂect the fact that only 60%–80%
of cells are infected by virus containing NICD2. These
Figure 1. GBM neurospheres are sensitive to NOTCH pathway blockade in vitro. (A): The GBM neurosphere line HSR-GBM1 grows as large,
multicellular spheres. The majority (70%) of neurosphere cells express CD133. (B): Upon GSI-18 treatment, protein levels of HES1, a NOTCH
pathway target gene, were reduced after 48 hours of GSI-18 treatment of HSR-GBM1 neurospheres. (C, D): Upon GSI-18 treatment, mRNA
expression of NOTCH target gene HES5 and protein levels of cleaved active NOTCH1 intracellular domain are also reduced. (E): GSI-18
reduced total cell mass in a dose-dependent fashion in all three HSR-GBM1 sublines (*, p < .05). (F): There is no signiﬁcant change in normal
human astrocyte growth when treated with GSI-18. (G): Growth of a second GBM neurosphere line, HSR-GBM2, was also inhibited by GSI-18.
(H): HES1 mRNA levels fell into a similar range in primary GBM and tumor-derived neurospheres grown in culture. (I): A second c-secretase
inhibitor, MRK-003, could also suppress GBM neurosphere growth. (J): MRK003 showed potency similar to GSI-18 in terms of its ability to
lower HES1 mRNA levels in tumor neurospheres. (K, L): Low-passage neurospheres GBM-SC, GBM-KK, and GBM-DM express the NOTCH
target gene HEY1 and had their growth inhibited by NOTCH blockade. Abbreviations: DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-
phosphate dehydrogenase; GBM, glioblastoma; GSI-18, c-secretase inhibitor 18.
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ﬁndings suggest that activation of NOTCH2 is sufﬁcient to
promote GBM neurosphere growth in vitro.
NOTCH Blockade Depletes CD133-Positive Cells
and Inhibits Neurosphere Clonogenicity
We have previously shown that CD133 marks cells with xen-
ograft-initiating potential [42, 49], and that NOTCH blockade
can deplete stem-like cells in medulloblastoma cultures [42].
In HSR-GBM1 neurospheres, we found an approximately
twofold increase in the clonogenic potential of CD133-posi-
tive cells compared with negative ones (C.G.E. and E. Bar,
unpublished data). We examined CD133 mRNA levels in
HSR-GBM1 cells after NOTCH pathway blockade by GSI-18,
and found that this stem cell marker was almost completely
suppressed by 3-lM levels of the c-secretase inhibitor after
48 hours (Fig. 3A). We also identiﬁed a pronounced, dose-de-
pendent decrease in the percentage of CD133-expressing cells
using ﬂow cytometric analysis, suggesting that the cancer
stem cell fraction within the tumor had been depleted (Fig.
3B). Given the evidence from two recent studies showing that
the CD133-negative GBM population also forms xenografts in
nude mice [50, 51], suggesting that this marker may not mark
all CSCs, we also examined several other stem cell markers
including NESTIN, BMI1, and OLIG2. The expression of all
of these was also inhibited by GSI-18 in a dose-dependent
fashion, indicating a broad effect on potential CSC markers
(Fig. 3C–3E). We next examined clonogenicity after treatment
with 5 lM MRK-003 to document functional loss of clono-
genic CSCs. Some tumor neurospheres were still present in
culture after 5 days of NOTCH inhibition (Fig. 3F, upper
right panel), however, when these were dissociated, and equal
numbers of viable cells seeded into semisolid neurosphere
media, those that had previously been exposed to NOTCH
blockade could not form colonies (Fig. 3F, 3G). Similar but
less pronounced effects were seen with 2-lM levels of the c-
secretase inhibitor (Fig. 3G). These data demonstrate that
NOTCH pathway blockade depletes stem-like cells in GBM,
and decreases tumor clonogenic growth in vitro.
NOTCH Signaling Blockade Depletes Cells Required
for GBM Engraftment In Vivo
To extend our in vitro ﬁndings, we studied the effects of GSI-
18 on in vivo tumor growth. First, we treated GBM neuro-
spheres for 2 days with either GSI-18 or vehicle (DMSO) ex
vivo, long enough to remove most stem-like GBM cells based
on the in vitro experiments described above. We then injected
equal numbers of surviving cells, which were demonstrated to
be viable by trypan blue staining and vital count assays, sub-
cutaneously into nude mice. After monitored tumor growth
for more than 3 months, we found that GSI-18 pretreatment
completely inhibited the growth of subcutaneous HSR-GBM1
xenografts (Fig. 4A–4D). Large tumor masses formed at all
eight sites (Fig. 4A, 4B, asterisks) injected with cells in which
NOTCH signaling was continuously active, including
Figure 2. Activation of
NOTCH2 in glioblastoma (GBM)
neurospheres increases tumor
growth in vitro. (A): When the
active form of NOTCH2 receptor
(NICD2) was stably transfected
into HSR-GBM1a cells, receptor
mRNA levels were elevated. (B):
NICD2 protein expression was
also increased in NICD2 stably
transfected HSR-GBM1 neuro-
spheres detected by Western blot.
GAPDH was used as protein
loading control. (C): The NOTCH
target gene HES1 was also in-
duced in NICD2-transfected GBM
neurospheres. (D): Cell growth
was signiﬁcantly increased in
NICD2-transfected cells. (E):
Transient expression of NICD2 in
HSR-GBM1 neurospheres using
adenovirus vectors also increased
cell growth over 2 days. Abbrevi-
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nontreated (n ¼ 4) and vehicle (DMSO)-treated (n ¼ 4) cells
(Fig. 4A, 4B). In contrast, mice injected with an equal num-
ber of viable cells previously treated with 2 lM GSI-18 (n
¼ 6) were unable to efﬁciently form tumors, with small
lesions developing at only three of six injection sites (Fig.
4C). A comparison of growing tumor volumes in mock-,
DMSO-, and 2 lM GSI-18-treated xenografts is shown in
Figure 4D. The small xenografts that are formed from GSI-
18-treated GBM cells had a microscopic appearance quite
similar to those from DMSO-treated cells (Fig. 4E, 4F).
They contained abundant HES1 protein (Fig. 4G), indicating
that cells that survive NOTCH blockade and grow slowly
into small tumors in vivo eventually re-establish expression
of NOTCH pathway targets.
Figure 3. NOTCH blockade
depletes CD133-positive cells
and inhibits neurosphere clono-
genicity. (A): CD133 mRNA
levels were severely decreased
following GSI-18 treatment of
HSR-GBM1 cells. (B): The
percentage of CD133-positive
cells in these cultures was also
lowered by NOTCH blockade.
(C–E): mRNA levels of the
stem cell markers NESTIN,
BMI1, and OLIG2 were also
reduced in a dose-dependent
fashion following GSI-18 treat-
ment of HSR-GBM1 neuro-
spheres. (F, G): Growing
HSR-GBM1 cultures treated
for 5 days with c-secretase in-
hibitor can form some neuro-
spheres (right top panel), but
when equal numbers of
DMSO- and MRK003-treated
cells are seeded singly in meth-
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To determine whether downregulation of NOTCH signal-
ing prior to injection of GBM neurospheres also affects intra-
cranial tumor initiation, we treated HSR-GBM1 with 2 lM or
5 lM GSI-18 for 48 hours ex vivo to deplete CSCs, then ster-
eotactically injected 50,000 viable cells into mouse brains.
The same number of cells from DMSO-treated neurospheres
Figure 4. NOTCH signaling blockade depletes cells required for glioblastoma (GBM) propagation in vivo. (A–C): Large xenografts formed at
all eight sites (asterisk) injected with cells in which NOTCH signaling was active, including nontreated (n ¼ 4, A) and vehicle (DMSO)-treated
(n ¼ 4) cultures. Mice injected with equal number of viable cells previously treated with 2 lM GSI-18 (n ¼ 6) were unable to efﬁciently form
tumors, with small lesions developing at only three of six injection sites. (D): Tumor volume was dramatically reduced in mice engrafted with 2
lM GSI-18-pretreated cells compared with mice engrafted with mock or DMSO-pretreated cells. (E–G): The small subcutaneous xenografts that
formed from cells pretreated with GSI-18 appeared similar to control tumors, and expressed abundant amounts of the NOTCH pathway target
HES1 on immunohistochemical analysis. (H, I): Intracranial xenografts of HSR-GBM1 cells pretreated with DMSO or GSI-18 often invaded into
the subventricular space (H), and occasionally formed necrotic foci with pseudopalisading (I). (Original magniﬁcations both 100.) Abbrevia-
tions: DMSO, dimethyl sulfoxide; GSI-18, c-secretase inhibitor 18.
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was used as a positive control, with four mice included per
group. Mice were sacriﬁced when they showed neurological
signs suggesting tumor growth, and survival was used as the
primary endpoint for statistical analysis. We found that ani-
mals injected with GSI-18-pretreated GBM neurospheres did
form orthotopic xenografts and die, but had a signiﬁcantly
longer survival compared with those injected with DMSO-
treated tumor cells (p < .05, log-rank analysis). Microscopic
examination of the xenografts that formed from the GSI-18-
pretreated (Fig. 4H, 4I) and DMSO-pretreated (not shown)
GBM neurospheres failed to identify any signiﬁcant differen-
ces in the size or histopathological appearance of the glio-
mas, which were all large and inﬁltrative. Interestingly,
many of the tumor xenografts, both treated and nontreated,
showed a predilection for invasion and growth in the sub-
ependymal region around the ventricles (Fig. 4H and data
not shown), perhaps due to the capacity of this area to sup-
port the growth of stem and progenitor cells. In some large
tumors, pseudopalisading necrosis, a common feature of
glioblastoma, was also seen (Fig. 4I). The fact that tumor
neurosphere cultures pretreated with c-secretase inhibitor did
form large xenografts, albeit more slowly than controls, may
reﬂect the fact that our in vitro analysis suggests only a par-
tial depletion of CD133-positive cells following NOTCH
blockade.
Local Delivery of c-Secretase Inhibitors Slows
Growth of Intracranial GBM Xenografts
To mimic more closely the care of GBM patients, and to test
the effects of longer-term delivery of c-secretase inhibitor, we
also treated small intracranial tumors using local delivery of the
NOTCH inhibitor. We injected GBM neurospheres into mouse
brains and waited for 15 days, a time frame during which we
predict that small tumors should form based on prior xenograft
time-course studies. Polymer-based beads soaked with GSI-18
or DMSO were then surgically implanted into the tumor beds
as described previously [47]. To conﬁrm that GSI-18 prevented
GBM neurosphere propagation in vivo due to downregulation
of NOTCH signaling pathway, we also injected cells stably
transfected with NICD2, thereby constitutively activating
NOTCH2 signaling and rendering the cells insensitive to c-sec-
retase blockade. We monitored tumor growth at 6 weeks after
injection by MRI scanning in representative animals, and found
that DMSO (vehicle)-treated mice form large xenografts,
whereas GSI-18 treatment appeared to block formation of radio-
graphically detectable tumors (Fig. 5A). The NICD2 transfected
GBM neurospheres appeared to form larger intracranial xeno-
grafts, and were not sensitive to GSI-18 treatment (Fig. 5A).
When we compared the survival of the various groups, mice
treated with GSI-18 also had a signiﬁcantly prolonged survival
Figure 5. Local GSI treatment prolongs survival of mice bearing intracranial GBM xenografts. (A): Wild-type or NICD2 stably transfected
GBM neurospheres were implanted into mouse brain, and GSI-18- or DMSO-soaked beads were injected into the tumor beds 2 weeks later. Tu-
mor growth was monitored by MRI in selected animals, and large xenografts formed in DMSO- but not GSI-18-treated mice. As expected, con-
stitutive NICD2 expression rendered xenografts insensitive to GSI-18. (B): GSI-18-treated mice have signiﬁcantly prolonged survival compared
with DMSO-treated mice, whereas expression of activated NOTCH2 promoted more rapid intracranial tumor growth. (C–E): Microscopic exami-
nation of a GSI-18-treated mouse brain stained with H&E reveals a round polymer bead (arrow) with a pale linear injection tract leading upward
(arrowhead), but no tumor mass on this or additional step sections (original magniﬁcation 100). Immunocytochemical stains using an antibody
speciﬁc for human nuclei conﬁrms the absence of viable tumor cells (D, E). (Original magniﬁcation 100.) Abbreviations: DAPI, 40,6-diami-
dino-2-phenylindole; DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GBM, glioblastoma; GSI-18, c-secretase
inhibitor 18; Hu, human nuclei; MRI, magnetic resonance imaging; NICD2, NOTCH2 intracellular domain.
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compared with DMSO-treated mice, whereas animals bearing
NICD2 xenografts had shorter survival and were not sensitive
to the GSI-18 treatment (Fig. 5B). Microscopic examination of
brains from treated animals revealed implanted polymer beads
and adjacent injection tracts but no recognizable surviving tu-
mor cells in the multiple sections examined (Fig. 5C). Immuno-
cytochemical analysis of intervening sections with anti-human
antibodies that can recognize xenografted cells also failed to
identify glioma (Fig. 5D, 5E). Thus signiﬁcant tumor growth is
blocked in most animals following local delivery of c-secretase
inhibitor.
NOTCH Blockade Selectively Reduces Proliferation
of Stem-Like GBM Cells
To examine the mechanism by which NOTCH regulates
stem-like cells in GBM, we used double immunolabeling to
assess proliferation in cells expressing the stem/progenitor
markers. Because it has been shown that NOTCH regulates
NESTIN expression in GBM [52], raising the possibility that
population changes could be due to direct effects of NOTCH
blockade on NESTIN levels rather than loss of stem-like
cells, we used both NESTIN and CD133 as markers. Consist-
ent with the concept that ongoing NOTCH signaling is
required in poorly differentiated cells, we found that pathway
blockade by GSI-18 signiﬁcantly reduced the percentage of
cells expressing high levels of NESTIN or CD133 in GBM
neurospheres (Fig. 6A, 6B). The overall Ki-67-positive prolif-
erating fraction of cells was also signiﬁcantly reduced (Fig.
6B). Importantly, proliferation rates were most dramatically
lowered by GSI-18 in the NESTIN- or CD133-bright popula-
tion, whereas NESTIN- or CD133-dim cells showed a far
lesser reduction in cycling cells (Fig. 6C, 6D). This suggests
that NOTCH inhibition depletes the stem-like tumor subpopu-
lation at least in part due to reduced proliferation. Although it
is not entirely clear how the proliferation rate of stem-like gli-
oma cells might affect tumor growth, it has recently been
shown that the presence of a high percentage of glioblastoma
cells coexpressing CD133 and Ki-67 is associated with worse
clinical outcomes [53].
NOTCH Signaling Regulates Phosphorylation of
Akt and STAT3 in GBM Neurospheres
To address the possibility that NOTCH blockade induces cell
death in GBM neurosphere cells, as well as decreasing prolif-
eration, we examined cleavage of caspase-3 following GSI-18
treatment. An increase in the proapoptotic cleaved form of
this protein was identiﬁed in cultures treated with 0.4 lM and
higher levels of the NOTCH pathway inhibitor, suggesting
that cell death was induced by NOTCH blockade (Fig. 7). We
also wanted to identify the downstream targets that might
mediate the apoptotic effects of NOTCH pathway blockade in
GBM neurospheres. AKT and p53 are two key proteins that
regulate apoptosis in many type of cancers [54]. We therefore
examined whether protein levels or phosphorylation states of
p53 and AKT were changed in GSI-18-treated GBM neuro-
spheres. We did not observe p53 alteration in GSI-18-treated
GBM cells (data not shown). However, 2 lM GSI-18 totally
blocked AKT phosphorylation (pAKT-Ser473) in the GBM
neurosphere line HSR-GBM1 (Fig. 7). These results suggest
that phosphorylation and activation of AKT promoted by
NOTCH may mediate survival of GBM CSCs. Recently, it
Figure 6. NOTCH signaling regulates proliferation of poorly differentiated GBM cells. (A): NOTCH pathway blockade by GSI-18 reduces the
NESTIN- or CD133-positive population in neurosphere lines, as assessed by double immunolabeling (upper panel: NESTIN in green; Ki-67, red;
DAPI, blue; lower panel: CD133 in red; Ki-67, green; DAPI, blue). (B): Both NESTIN- and Ki-67-positive populations were signiﬁcantly
reduced. (C, D): Ki-67 proliferation indices were signiﬁcantly lowered by GSI-18 in the NESTIN- or CD133-positive cell population, whereas
NESTIN- or CD133-negative cells showed a lesser reduction (p value for t tests: *, p < .05, **, p < .01). Abbreviations: DAPI, 40,6-diamidino-
2-phenylindole; DMSO, dimethyl sulfoxide; GSI-18, c-secretase inhibitor 18.
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has been shown that NOTCH signaling can regulate stem cell
numbers both in vitro and in vivo through phosphorylation of
STAT3 (pS727) [55]. To determine whether STAT3 might
also be affected by NOTCH inhibition in brain tumors, we
examined pSTAT3 protein changes in GSI-18-treated HSR-
GBM1 neurospheres. We found that phosphorylation of
STAT3 was signiﬁcantly reduced by NOTCH pathway block-
ade in a dose-dependent fashion, whereas total STAT3 was
essentially unchanged in GSI-18-treated HSR-GBM1 neuro-
spheres (Fig. 7). These results suggested that NOTCH signal-
ing may regulate GBM CSC survival through phosphorylation
of AKT and STAT3.
DISCUSSION
A number of groups analyzing GBM have identiﬁed molecular
changes in NOTCH pathway members, implicating activation
of this developmentally important signaling cascade in the path-
obiology of malignant brain tumors [9, 12, 32]. In the current
study, we used neurospheres derived from human GBM speci-
mens to examine the effects of NOTCH pathway blockade.
Such neurosphere lines represent an improved model system, as
when injected orthotopically into immunocompromised mice
they recapitulate the pathobiology of GBM more closely than
traditional adherent cell lines maintained in high serum. Both
established and lower-passage neurosphere cultures were used.
We found that NOTCH pathway blockade by either of two
structurally distinct c-secretase inhibitors slows tumor growth in
all GBM neurosphere cultures tested, whereas overexpression of
a constitutively active form of NOTCH2 increases tumor
growth. In addition, we demonstrate that NOTCH pathway
blockade inhibits GBM neurosphere engraftment in vivo, and
signiﬁcantly prolongs the survival of mice bearing intracranial
xenografts. Larger preclinical studies will be needed to conﬁrm
and extend these data.
It has been suggested that NOTCH may play a particu-
larly important role in CSCs, a subpopulation of tumor cells
that have stem-like properties and are uniquely capable of en-
abling engraftment and long-term growth of cancers [5–10,
32, 56–58]. Although a few gain-of-function studies directly
support the concept that NOTCH is important in stem-like
GBM cells [52, 59], to our knowledge it has not been shown
that NOTCH pathway inhibition can deplete CSCs in gliomas.
We found that pharmacological NOTCH blockade using c-
secretase inhibitors reduces the percentage of cells expressing
the stem/progenitor cell markers CD133 and NESTIN in
GBM neurospheres. In addition, following NOTCH blockade,
surviving cells are no longer able to efﬁciently form colonies
in vitro or engraft in vivo, consistent with the concept that a
key subpopulation of cells required for efﬁcient tumor propa-
gation is no longer present. We believe that the depletion of
the GBM subpopulation expressing stem cell markers, in con-
junction with the loss of clonogenic and engraftment poten-
tial, suggests that NOTCH blockade can at least partially
remove CSCs from GBM neurosphere lines.
Gastrointestinal toxicity has been a major concern when
using GSI, with NOTCH blockade inducing goblet cell differ-
entiation in intestinal transit amplifying cells, leading to
severe diarrhea [60–63]. To avoid such side effects, we used
polymer-based beads to deliver GSI-18 locally within the
brain in our in vivo experiments. This method is conceptually
Figure 7. NOTCH signaling blockade promotes caspase-3 cleavage and reduces phosphorylation of AKT and STAT3. (A): Loss of AKT and
STAT3 phosphorylation and activation of caspase-3 cleavage is induced by 2 lM or higher levels of GSI-18, whereas overall levels of AKT and
STAT3 are unchanged in GBM neurosphere cells. GAPDH is used as a loading control. These changes were quantitated using densitometry in
(B–D). Abbreviations: DMSO, dimethyl sulfoxide; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GBM, glioblastoma; GSI-18, c-secretase
inhibitor 18.
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similar to local delivery of the chemotherapeutic agent biode-
gradable carmustine via polymer wafers to the tumor bed, a
Food and Drug Administration (FDA)-approved strategy cur-
rently used in GBM patients [64–67]. The fact that this local
delivery of GSI-18 signiﬁcantly prolongs survival without any
detectable gastrointestinal side effects in animals suggests a
strategy for translating GSI-based therapies into neuro-oncol-
ogy clinics. One additional potential concern when targeting
CSCs in the brain is that NOTCH inhibition may also deplete
normal neural stem cells. However, we did not ﬁnd obvious
neurological defects in the animal receiving GSI over several
months of observation.
To maximize the efﬁcacy of anti-CSC agents such as c-
secretase inhibitors, it will likely be necessary to give them in
combination with other treatment modalities (surgery, radia-
tion therapy, other chemotherapy). Indeed, it has recently
been shown that giving a c-secretase inhibitor in conjunction
with the glucocorticoid dexamethasone can potentiate its ther-
apeutic effect and reduce systemic side effects when treating
leukemia [68]. In this regard, our discovery that the reduced
proliferation and induction of apoptotic markers in GBM fol-
lowing NOTCH blockade is associated with phosphorylation
changes to AKT and STAT3 suggests additional pathways
that might be synergistically targeted.
SUMMARY
In summary, our data support the concept that c-secretase
inhibitors can inhibit the growth of functionally heterogeneous
GBM neurospheres, both in vitro and in vivo, with particu-
larly pronounced effects on poorly differentiated tumor cells.
The potential therapeutic implications of targeting of stem-
like cells via NOTCH inhibition extend beyond neuro-oncol-
ogy, as this signaling pathway has been shown to play a role
in CSCs not only in neural tumors, but also in cancers from
breast, lung, pancreas, and prostate [26, 69–72]. More studies
will be needed to determine whether pharmacological
NOTCH blockade, either alone or in conjunction with other
therapies, will be effective in improving the survival of
patients with GBM and other malignant tumors.
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